PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2
Work
Year: 2024
Type: article
Source: Journal of Thoracic Oncology
Cites:
Cited by: 12
Related to: 10
FWCI: 9.566
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Zero hunger
Open Access status: closed